Sorafenib, an oral multi-kinase inhibitor, is the final therapy prior to palliative care for advanced hepatocellular carcinoma (HCC). However, due to its adverse effects, 20% of patients must discontinue sorafenib within 1 month after first administration. To identify ways to predict the adverse effects and administer the drug for longer periods, we explored the relationship between the duration of sorafenib treatment and the pharmacokinetics of sorafenib and its major metabolite, sorafenib N-oxide. Twenty-five subjects enrolled in the study were divided into two groups: patients with dosage reduced or withdrawn due to adverse effects (n = 8), and patients with dosage maintained for 1 month after initial administration (n = 17). We evaluated early sorafenib accumulation as the area under the curve of sorafenib and sorafenib N-oxide concentrations during days 1-7 (AUC sorafenib and AUC N-oxide , respectively). Inter-group comparison revealed that AUC N-oxide and AUC ratio (AUC N-oxide /AUC sorafenib ) were significantly higher in the dosage reduction/withdrawal group (P = 0.031 and P = 0.0022, respectively). Receiver operating characteristic analysis indicated that AUC N-oxide and AUC ratio were reliable predictors of adverse effects. When patients were classified by cut-off points (AUC N-oxide : 2.0 μg•day/mL, AUC ratio: 0.13), progression-free survival was significantly longer in patients with AUC N-oxide ≤ 2.0 μg•day/mL (P = 0.0048, log-rank test). In conclusion, we recommend to simultaneously monitor serum levels of sorafenib and its N-oxide during the early stage after the first administration, which enables us to provide safe and long-term therapy for each HCC patient with sorafenib.
Introduction
Sorafenib is the world's first oral molecularly targeted drug approved for treatment of patients with advanced or metastatic renal-cell carcinoma . The drug was approved in the U.S.A. in December 2005. In Japan, sorafenib was approved in January 2008 for the same indications, and subsequently approved in May 2009 for treatment of patients with hepatocellular carcinoma (HCC) judged to be unresectable or refractory to transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA). In June 2014, the drug was approved for the treatment of patients with locally advanced or metastatic differentiated thyroid cancer (http://www.info.pmda.go.jp/ go/interview/1/630004_4291017F1025_1_1F).
Because sorafenib is the final therapy prior to palliative care for HCC patients, it is important that administration be continued as long as possible. However, according to the second interim report of Nexbar ® Special Drug Use Surveillance for HCC (Bayer Yakuhin, Osaka, Japan), adverse effects force 20% of patients to discontinue sorafenib within 1 month after the first administration. Diarrhea, rash, fatigue, hand-foot skin reactions, and hypertension are the most common adverse events associated with sorafenib. Serious adverse effects such as liver failure, hepatic encephalopathy, and pneumonitis also arise in some cases (http:// www.nexavar.jp/unmember/pdf/hcc201205.pdf).
Sorafenib is absorbed from the gastrointestinal tract and reaches the liver via the portal vein. Therefore, its bioavailability is influenced by the activity of the excretory transporters ABCB1 and ABCG2 in the small-intestinal mucosa (Hu et al. 2009; Gnoth et al. 2010 ). In addition, sorafenib is primarily metabolized by cytochrome P450 3A4 (CYP3A4) in the small-intestinal mucosa or the liver, and it is also subjected to glucuronidation mediated by uridine diphosphate glucuronosyl transferase (UGT) 1A9 (Lathia et al. 2006; Peer et al. 2012; Filppula et al. 2014) .
Sorafenib and its metabolites are predominantly passed in the feces, whereas a portion of the glucuronide is broken down to sorafenib by β-glucuronidase expressed by bacterial flora in the intestine. Subsequently, sorafenib undergoes enterohepatic circulation and reaches steady state within 7-10 days after administration is initiated (http:// www.info.pmda.go.jp/go/interview/1/630004_4291017F10 25_1_1F; van Erp et al. 2009 ). According to a safety information letter from the Ministry of Health, Labour and Welfare of Japan (November 18, 2009 ), signs of serious adverse effects are observed in patients' laboratory results within 1 week after the first administration (http://www. mhlw.go.jp/file/06-Seisakujouhou-11120000-Iyakush okuhinkyoku/0000076332.pdf). Together, these observations suggest that knowledge of the pharmacokinetics of sorafenib might be useful in avoiding adverse effects during the early stages of administration of this drug.
Recently, Blanchet et al. (2009) reported that the plasma concentration of sorafenib in patients with adverse effects (grade > 3) is 1.5-fold higher than in patients with no adverse effects. Boudou-Rouquette et al. (2012) also reported that the AUC of sorafenib is associated with the highest risk of developing any type of grade ≥ 3 toxicity.
Therefore, we started therapeutic drug monitoring of the trough levels of sorafenib and its major metabolite, sorafenib N-oxide, during hospital stays and in the outpatient clinic. In this study, we investigated the association between adverse effects and the accumulation of sorafenib and its N-oxide, with the goal of providing safe and longterm sorafenib therapy for patients with HCC.
Human Subjects and Methods

Human subjects
This research was conducted as an observational study. The institutional committee of the Graduate School of Medicine at Tohoku University approved the use of human subjects in this study. Twentyfive HCC patients treated with sorafenib at Tohoku University Hospital were enrolled. Patients provided written informed consent according to the protocol adopted by the institutional review board of the Graduate School of Medicine at Tohoku University in February 2011. Characteristics of these patients undergoing sorafenib treatment are provided in Table 1 . The first dose of sorafenib was determined by the attending doctor based on the hepatic functional reserve of each patient. When the frequency of administration changed to once per day, sorafenib was taken after breakfast.
Dosage-reduction or withdrawal criteria for sorafenib administration
Sorafenib-related adverse effects were graded according to the National Cancer Institute Common Terminology Criteria for adverse events, version 4.0. The reference ranges of neutrophil counts, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) in Tohoku University Hospital were 1.64-5.95 × 10 3 cells/μL, 8-38 IU/L, 4-43 IU/L, and 115-330 IU/L, respectively. The attending doctor made decisions about dosage reduction or withdrawal of sorafenib treatment according to the criteria described in the package insert.
Blood sampling
Peripheral blood samples (2 ml each) were collected in noncoated blood collection tubes. For hospitalized patients, samples were taken at trough in the morning (AM 6:00) every other day during the hospital stay. For outpatients, samples were taken every 2-4 weeks during hospital visits , along with routine biochemical blood tests. After blood collection, while waiting to see the doctor, outpatients ate breakfast, followed by administration of sorafenib. After centrifugation of the blood collection tubes, serum samples were obtained and analyzed following the protocols described below. Residual serum was stored at −80°C.
Preparation of analytical samples
First, 200 μL of IS (internal standard) solution (5 μg/mL) was added to 200 μL of serum in a glass tube. After mixing for 10 s, the tube was centrifuged at 1,580 g for 10 min. An aliquot (300 μL) of the supernatant was transferred into a plastic tube (1.5 mL) containing 75 μL of deionized purified water. Next, 250 μL of the resulting solution was applied to a Bond Elut C18 column (100 mg/1 mL, Agilent Technologies, Inc., Santa Clara, CA, USA), which was washed with 600 μL of 40% acetonitrile. The analytes were eluted with 1,000 μL of acetonitrile, and the eluate was evaporated to dryness under a nitrogen gas stream. The residue was reconstituted in 100 μL of 20 mM ammonium acetate buffer (pH 4.0)/acetonitrile (30:70, v/v) . An aliquot (5 µL) was analyzed by HPLC. Details were described in a previous report (Shimada et al. 2014) .
Determination of sorafenib and its major metabolite, sorafenib N-oxide
Sorafenib and sorafenib N-oxide were determined simultaneously using a liquid chromatography system (Agilent 1100) consisting of a pump with degas option, autosampler, and UV detector (Agilent Technologies, Inc.). Chromatographic separation was achieved on an Inertsil ODS-3 column (2.1 mm i.d. × 150 mm, 5 μm, GL Science, Inc., Tokyo, Japan) associated with a guard column packed with the same material. The composition of the mobile phase was 20 mM ammonium acetate buffer (pH 4.0)/acetonitrile (30:70, v/ v). The flow rate was 200 μL/min throughout the 15-min run. The eluent was monitored at a wavelength of 265 nm. The intra-assay and inter-assay coefficients of variation and accuracy bias were less than 15% (Shimada et al. 2014 ).
Evaluation of cumulative sorafenib and sorafenib N-oxide
The cumulative area under the concentration-time curve (AUC) between day 1 and day 7 was calculated according to the trapezoidal rule using the Excel 2010 software (Microsoft, Redmond, WA, USA). AUC of sorafenib and sorafenib N-oxide during days 1-7 were described as AUC sorafenib and AUC N-oxide , respectively. AUC N-oxide / AUC sorafenib was described as the AUC ratio.
Performance evaluation
Receiver Operating Characteristic (ROC) curves were constructed using the AUC N-oxide or AUC ratio, as well as adverse effects resulting in dosage reduction or withdrawal, from 25 patients with HCC (Zweig and Campbell 1993; Muller et al. 2007; Harmon et al. 2011) . The area under the ROC curves (AUC ROC ) was calculated, and the statistical significance was tested using nonparametric assumptions. ROC curves can reveal the efficacy of a test by providing information about both sensitivity and specificity at different cut-off points. Sensitivity and specificity measure the ability of a test to distinguish true and false positives within a dataset. Kaplan-Meier analysis was performed to compare the progression-free survival period (PFSP) between patients with AUC N-oxide ≤ 2.0 μg•day/mL and those with AUC N-oxide > 2.0 μg•day/mL. Cox proportional hazards models were used to examine the effects of AUC N-oxide > 2.0 μg•day/mL and AUC ratio > 0.13 on the duration of treatment with sorafenib. The results are reported as risk ratio with 95% CI.
Statistical analysis
Comparisons of means of the two groups (dosage reduced or withdrawn vs. dosage maintained) were performed using the independent samples Mann-Whitney U test. P values less than 0.05 were considered to represent statistically significant differences. All statistical analysis and figure preparation was performed using the Excel 2010 software. Kaplan-Meier and Cox proportional hazards model analyses were performed using JMP Pro (ver.11.0; SAS Institute, Cary, NC, USA).
Results
Association between serum sorafenib concentration and adverse effects
Hand-foot skin reaction (grade 2) and intense lassitude were observed in an HCC patient treated with the recommended daily dose of sorafenib (400 mg b.i.d.) at an outpatient clinic 56 days after the first administration. The attending doctor elected to give a smaller dose (400 mg once daily after breakfast). After 2 weeks (70 days after initiation of administration), the severity of the skin reaction was reduced. In this patient, the serum concentration of sorafenib was 2.6 μg/mL at discharge (day 9), 6.1 μg/mL on day 56, and 4.1 μg/mL on day 70 (Fig. 1) . These results suggest that serum sorafenib concentration is associated with the drug's adverse effects.
Patient status before and after taking sorafenib
Sera from 25 patients taking sorafenib were obtained immediately before the first administration (1 day), and then blood samples were collected at least three times within the next 7 days, during hospitalization. Characteristics of these patients are shown in Table 1 . For patients who experienced a dosage reduction or withdrawal within 1 month of initiating sorafenib treatment, the details reasons are provided in 
AUC sorafenib , AUC N-oxide , and AUC ratio in patients taking sorafenib
We calculated AUC sorafenib and AUC N-oxide from day 1 to day 7. The AUC ratio (AUC N-oxide /AUC sorafenib ) was also calculated during the same interval. Individual patients' AUC data are also shown in Table 2 . We observed a greater than 10-fold inter-individual difference in the values of AUC sorafenib , AUC N-oxide , and AUC ratio among 22 patients, despite the fact that the same dosages (800 mg/day) were administered.
When we examined the reciprocal relationship among AUC sorafenib , AUC N-oxide , and AUC ratio, we found that the decision coefficients (r 2 ) of AUC N-oxide vs. AUC sorafenib , AUC N-oxide vs. AUC ratio, and AUC sorafenib vs. AUC ratio were 0.82 (P < 0.0001), 0.42 (P < 0.0004), and 0.095 (P = 0.1347), respectively (Fig. 2) .
Correlation between adverse effects and AUC sorafenib , AUC N-oxide , and AUC ratio
We compared AUC sorafenib , AUC N-oxide , and AUC ratio between a group that underwent dosage reduction or withdrawal (8 patients) and a group in which dosage was maintained for 1 month (17 patients). Statistical comparisons were performed using the Mann-Whitney U test. As shown in Fig. 3 , AUC sorafenib was higher in the dosage reduction/ withdrawal group than in the dosage maintenance group, although statistical comparison revealed no significant differences (P = 0.19). AUC N-oxide and AUC ratio were significantly higher in the dosage reduction/withdrawal group (AUC N-oxide : P = 0.031, AUC ratio: P = 0.0022).
Accuracy of AUC N-oxide and AUC ratio as predictive factors
In light of the association between AUC N-oxide or AUC ratio and dose reduction or withdrawal within 1 month, we performed ROC curve analysis. The AUC N-oxide cut-off for response discrimination was determined from the point on the ROC curve with the minimum distance from the point corresponding to sensitivity and specificity values of 1.0 (Schisterman et al. 2005) (Fig. 4) . The calculated cutoff values for AUC N-oxide and AUC ratio were 2.0 μg•day/mL and 0.13, respectively. In general, prediction accuracy was evaluated using the AUC ROC . AUC ROC of AUC N-oxide and AUC ratio were 0.76 and 0.86, respectively. These results suggest that, compared to AUC N-oxide , AUC ratio is a superior predictor of adverse effects within 1 month after initial administration of sorafenib. Using these cut-off values, sensitivity and specificity of AUC N-oxide were 0.88 and 0.76, respectively, whereas sensitivity and specificity of AUC ratio were 1.0 and 0.59, respectively.
Elimination half-life (t 1/2 ) values of sorafenib and sorafenib N-oxide during the washout period in the patients taking sorafenib
To determine the relationship between adverse effects and accumulation of sorafenib, we calculated the t 1/2 values during the washout period after treatment was abandoned due to adverse effects. Two patients presented with both neutropenia and skin disorder (No. 5 and No. 24) . The t 1/2 values of sorafenib and sorafenib N-oxide during the washout period were 15 h and 20 h, respectively, in patient No. 5, and 16 h and 22 h, respectively, in patient No. 24. On the other hand, the t 1/2 values of sorafenib and sorafenib N-oxide in two patients with skin disorders alone were 10 h and 8.6 h, respectively, in patient No. 6, and 11 h and 12 h, respectively, in patient No. 11. Based on these calculations, the t 1/2 values of sorafenib and sorafenib N-oxide were 1.5-and 2-hold higher, respectively, in patients with both neutropenia and skin disorder than in patients with skin disorders alone.
Associations of AUC N-oxide and AUC ratio with progressionfree survival period of sorafenib treatment
Of the 25 patients enrolled in this study, eight who underwent dosage reduction or withdrawal for l month due to adverse effects, six (Nos. 1, 4, 8, 12, 13, 22) who transferred to their nearest hospital, and one (No. 20) who withdrew were counted as "censored". In other patients, we defined the date when their condition became exacerbated as the day when they were immediately hospitalized or died due to aggravation of primary disease or overall status (Nos. 3, 10, 15, 17, 18, 19, 23, 25) , and complained of intense lassitude (Nos. 7, 16). Therefore, we divided 25 patients into two groups according to the cutoff points of AUC N-oxide (2.0 μg•day/mL) or AUC ratio (0.13). The median PFSP in the patients with AUC N-oxide ≤ 2.0 μg•day/mL (n = 14, 7 patients censored) and that with AUC N-oxide > 2.0 μg•day/mL (n = 11, 8 patients censored) were 380 (95% CI, 207-610) and 150 (95% CI, 142-152) days, respectively (Table 3) ; the median PFSP in patients with AUC ratio ≤ 0.13 (n = 10, 5 patients censored) and that with AUC ratio > 0.13 (n = 15, 10 patients censored) were 380 (95% CI, 184-839) and 150 (95% CI, 144-276) days, respectively. When patients were grouped by their AUC N-oxide and AUC ratio values, Kaplan-Meier analysis revealed a statistically significant difference in PSFP between patients with AUC N-oxide ≤ 2.0 μg•day/mL and those with AUC N-oxide > 2.0 μg•day/mL (log-rank test; P = 0.0048) (Fig. 5A) . PFSP did not differ significantly between patients with AUC ratio ≤ 0.13 and patients with AUC ratio > 0.13 (log-rank test; P = 0.1248) (Fig. 5B) .
We next examined the effects of AUC N-oxide > 2.0 μg•day/mL and AUC ratio > 0.13 on PFSP using the Cox proportional hazards model (Table 2) . When patients were grouped according to their AUC N-oxide , PFSP was significantly longer for patients with AUC N-oxide ≤ 2.0 μg•day/mL than for patients with AUC N-oxide > 2.0 μg•day/mL (risk ratio, 0.081; 95% CI, 0.0040-0.64; P (Prob>Chisq) = 0.0173). When patients were grouped according to their AUC ratio, PFSP did not differ significantly between patients with AUC ratio ≤ 0.13 and patients with AUC ratio > 0.13 (risk ratio, 0.39; 95% CI, 0.11-1.4; P (Prob>Chisq) = 0.1534).
In patients with treatment durations greater than 6 months, the values of AUC sorafenib , AUC N-oxide , and AUC ratio were 7.7 ± 1.9 μg•day/mL, 1.13 ± 0.56 μg•day/mL, and 0.14 ± 0.054, respectively. From the corresponding AUC values, the trough levels of sorafenib and sorafenib N-oxide were back-calculated as approximately 2.0 and 0.28 μg/mL, respectively.
Discussion
To continue treatment of patients with molecularly targeted drugs for extended periods of time, it is preferred to identify the predictors for adverse effects of these drugs. To date, data regarding determinants of sorafenib-induced toxicity remain scarce. Studies to data have reported an association of age and therapy discontinuation in Japanese patients (Morimoto et al. 2011) ; associations of cumulative sorafenib dose, Eastern Cooperative Oncology Group (ECOG) PS, and female gender with hand-foot skin reaction (Azad et al. 2009; Dranitsaris et al. 2012) ; and an association of UGT1A9-2152 T allele with grade ≥ 2 diarrhea (Boudou-Rouquette et al. 2012). To determine the effect of drug accumulation on drug-induced toxicity in the context of clinical use of sorafenib, AUC analysis must be applied. While monitoring the serum level of sorafenib in one patient, we observed an adverse effect, hand-foot skin reaction (G2), accompanied by an increase in the trough Comparisons of quartiles between the two groups were performed using the Mann-Whitney U test. P values less than 0.05 were considered to represent statistically significant differences. sorafenib level. This observation was similar to those in other reports (Blanchet et al. 2009; Boudou-Rouquette et al. 2012) and suggests that sorafenib-related adverse effects are correlated with serum concentration of the drug. Therefore, we ascertained the association between dosage reduction/withdrawal of sorafenib and the AUC of sorafenib or sorafenib N-oxide during days 1-7 in 25 patients with HCC. We showed for the first time that the AUC of the sorafenib N-oxide concentration (AUC N-oxide ) during days 1-7 and the AUC N-oxide /AUC sorafenib ratio during the same interval are determinants of the development of adverse effect leading to dosage reduction or withdrawal, and that AUC N-oxide and AUC ratio are predictive of adverse effects. Boudou-Rouquette et al. (2012) found that AUC of sorafenib during days 1-30 was associated with the occurrence of any type of grade ≥ 3 toxicity, whereas we did not observe that the AUC of sorafenib during days 1-7 was significantly higher in the dosage reduction/withdrawal group than in the dosage maintenance group. We observed a good correlation between AUC sorafenib and AUC N-oxide (r 2 = 0.82, P < 0.0001, Fig. 2A ), suggesting that the serum concentration of N-oxide increased along with the concentration of sorafenib within the observed concentration range. It is possible that a larger population analysis might reveal that AUC sorafenib is also a predictor of adverse effects.
Although only 25 patients enrolled in this study, we were able to use ROC analysis to detect an association between the pharmacokinetics of sorafenib and its N-oxide and adverse effects occurring within the first month of sorafenib therapy. The AUC ROC of AUC N-oxide and AUC ratio were 0.76 and 0.86, respectively, indicating that these predictors were of moderate accuracy.
However, the detailed mechanism underlying the association between the AUC ratio or AUC N-oxide and the occurrence of adverse effects remains obscure. According to the Nexavar ® interview form, the geometric average for AUC of [ 14 C]sorafenib in male rat skin is 86.4 mg•eq•h/L, close to the value in blood. Meanwhile, the t 1/2 of [ 14 C]sorafenib in skin was highest overall among the tissues examined, and seven times higher than that in blood. These results suggest that sorafenib and its metabolites, including sorafenib N-oxide, accumulate in rat skin. In histopathological studies of skin toxicity associated with sorafenib in humans, the most relevant findings included keratinocyte vacuolar degeneration, the presence of intracytoplasmic eosinophilic bodies, and intraepidermal blisters in the stratum malpighii (Yang et al. 2008) . Sorafenib is a multi-kinase inhibitor initially developed to inhibit the Raf1 kinase pathway (Smith et al. 2001; Lowinger et al. 2002) . In addition to inhibiting tumor-cell proliferation by targeting the Raf/MEK/ERK signaling pathway, sorafenib also inhibits angiogenesis by targeting tyrosine kinases such as vascular-endothelial growth factor receptor (VEGFR-2 and VEGFR-3), plateletderived growth factor receptor (PDGFR), Fms-like tyrosine kinase (FLT)-3, and c-KIT (Gollob 2005; Carlomagno et al. 2006; Liu et al. 2006; Wilhelm et al. 2006) . Sorafenib also induces apoptosis in tumor cells via signal transducer and activator of transcription (STAT)-3 (Chen et al. 2010) . Some reports have shown that the PDGF-PDGFβ receptor signal is a major proliferative and migratory stimulus for connective tissue cells during the initiation of skin-repair processes in human keratinocytes (Ansel et al. 1993; Rollman et al. 2003) . According to the data from the interview form, sorafenib N-oxide inhibits PDGFR-β kinase four times more strongly than sorafenib (IC 50 : 14 vs. 57 nM).
Further, Rolny et al. (2006) reported that PDGFR-β signal plays an important role in early hematopoietic development, suggesting that a decline in the PDGFR-β signal may explain the lower neutrophil counts. Combined with difference in t 1/2 values of sorafenib and sorafenib N-oxide between patients with both neutropenia and skin disorder and those with skin disorders alone, these data indicate that accumulation of sorafenib N-oxide, as well as sorafenib, causes severe neutropenia. Taken together, these data imply that accumulation of sorafenib N-oxide is associated with cutaneous skin toxicity or neutropenia via PDGFβ kinase inhibition, which is a reason for selecting AUC N-oxide and AUC ratio as predictive factors for sorafenib-induced toxicity at early stages after the first administration.
In the following, we further discuss the factors associated with risk of accumulating sorafenib N-oxide. In one patient with underlying intrahepatic bile duct dilatation (No. 9), the ALP value was increased by 802 U/L on day 6 after sorafenib administration; consequently, sorafenib administration was stopped at that time. Bile duct obstruction is suspected to cause accumulation of sorafenib, a substrate for CYP3A4. Two patients (No. 11 and No. 24 ) who received combined long-term administration of predonine also had high values of AUC N-oxide and AUC ratio, possibly because predonine is an inducer of the CYP3A4 protein (Usui et al. 2003; Noda et al. 2013) . When patient No.11 was restarted at 400 mg/day of sorafenib (200 mg b.i.d) after suspension of treatment, AUC N-oxide and AUC ratio were 1.6 μg•day/mL and 0.21, respectively. Fifty days later, when no adverse effects had been observed in the patient, the attending doctor increased the dose to 600 mg (400 mg after breakfast and 200 mg after dinner), and treatment was subsequently maintained for 320 days. Based on these cases, it is possible that progression of primary diseases such as hepatitis and cirrhosis, the location of hepatocellular carcinoma, or concomitant administration of other drugs can influence the pharmacokinetic profile of sorafenib and sorafenib N-oxide, leading to adverse effects that ultimately result in dosage reduction/withdrawal. Patients taking sorafenib for a long period complained of diarrhea or intense lassitude. There are no detailed data available regarding the association of sorafenib or its N-oxide with long-term toxicity. Collectively, our result show that controlling the values of AUC N-oxide (≤ 2.0 μg•day/mL) and AUC ratio (≤ 0.13) makes it possible to prevent serious adverse effects at the early stage and continue long-term therapy.
This result should be confirmed in a future study involving a larger number of patients.
